-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ixabepilone and eribulin mesylate: two novel agents approved for the chemotherapeutic treatment ofmetastatic breast cancer
Yael S Zack, Linda T Vahdat
Review: Clinical Trail Outcomes: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
Denosumab open-label extension trial shows positive results for osteoporosis treatment
News and Views: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes, Ruben Mesa
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation